Having trouble accessing articles? Reset your cache.

Protectan: Preliminary Phase Ib data

Top-line data from a Phase Ib trial in 100 healthy volunteers showed that 4 dosing regimens of CBLB502 were well tolerated and produced rapid cytokine

Read the full 254 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE